Clicky

Jaguar Animal Health, Inc.(JAGX)

Description: Jaguar Animal Health, Inc., a development-stage animal health company, focuses on developing and commercializing gastrointestinal products for companion and production animals. The company's lead prescription drug product candidate includes Canalevia, a canine-specific formulation of Crofelemer for the treatment of CID and general acute watery diarrhea in dogs. It is also developing Crofelemer to treat acute colitis in horses and general acute watery diarrhea in cats; Neonorm, an enteric-coated tablet for scours in preweaned dairy calves, as well as other animal species, such as horses, goats, and sheep; and other product candidates, including Virend and NP-500. The company was founded in 2013 and is headquartered in San Francisco, California. Jaguar Animal Health, Inc. is a subsidiary of Napo Pharmaceuticals, Inc.


Keywords: Medicine Gastrointestinal Prescription Drugs Gastroenterology Diarrhea Dog Animal Health Colitis Drug Products Gastrointestinal Tract Gastrointestinal Products Prescription Drug Product

Home Page: jaguar.health

JAGX Technical Analysis

200 Pine Street
San Francisco, CA 94104
United States
Phone: 415 371 8300


Officers

Name Title
Ms. Lisa A. Conte Founder, CEO, Pres & Director
Mr. Jonathan S. Wolin CPA, J.D., M.B.A. Chief of Staff, Chief Compliance Officer & Gen. Counsel
Mr. Ian H. Wendt M.B.A. Chief Commercial Officer
Dr. Steven R. King Ph.D. Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec.
Ms. Carol R. Lizak Chief Financial Officer
Dr. Pravin R. Chaturvedi Ph.D. Chief Scientific Officer & Chair of Scientific Advisory Board
Mr. Peter Hodge Sr. Director of Investor Relations, Bus. Devel. & Special Events
Dr. Karen J. Brunke Ph.D. Exec. VP of Corp. & Bus. Devel.
Mr. David Sesin Chief Manufacturing Officer
Dr. Michael K. Guy D.V.M., M.S., Ph.D. VP of Preclinical & Nonclinical Studies

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.6525
Price-to-Sales TTM: 1.5423
IPO Date: 2015-05-13
Fiscal Year End: December
Full Time Employees: 52
Back to stocks